thought call jakafi price
solid thesi remain unchang continu believ jakafi
support stock could see better revenu diversif
jakafi beat us show strength franchis
believ long-term continu market leader see littl threat jakafi
domin myelofibrosi mf polycythemia vera pv long-term closest competitor
celgen fedratinib fda approv august mf howev state
call no/low impact fedratinib believ fedratinib
posit therapi base price market strategi in-lin view
despit posit view jakafi believ franchis well appreci street
remain quarter could see modest sentiment driven upsid surround nda
submiss capmatinib cholangiocarcinoma although receiv royalti
drug top-line readout itacitinib steroid-nav acut gvhd howev
interest event includ updat capmatinib bladder cancer
regulatori submiss topic ruxolitinib reemphas plan commerci
topic ruxolitinib us look partner ou given recent data last
quarter believ franchis could add meaning diversif jakafi revenu
unadjust revenu look updat regulatori file
next month pipelin asset could interest includ phase asset
parsaclisib sjgren autoimmun hemolyt anemia hidraden suppurativa
itacitinib ulcer coliti look bd remain unclear could see uptick
activ next year nonspecif call capac howev
compani cash interest ad hematology/oncolog asset state call
could play role next year overal remain neutral rate share reiter
tp await larger catalyst
model updates/risk non-gaap ep updat due revis
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari therapeut
oncolog hematolog dermatolog
blue sky upsid case valuat base fda
approv itacitinib steroid-nav gvhd pemigatinib
cholangiocarcinoma within next month also assum better
expect jakafi revenu
grey sky downsid valuat assum fda
approv pemigatinib itacitinib grey sky also assum neg data
readout pemigatinib urotheli cancer also assum jakafi
revenu lower expect
 close
pipelin updat file nda pemigatinib cholangiocarcinoma
enrol continu dose cohort phase pemigatinib
patient bladder cancer expect complet phase solid
tumor-agnost trial pemigatinib initi patient driver-activ
expect file nda capmatinib novarti partner receiv
royalti sale global net sale compani anticip data readout ruxolitinib
steroid-refractori chronic gvhd compani also expect gravitas-
trial itacitinib steroid-nav gvhd phase itacitinib
steroid-na chronic gvhd initi januari year result expect
model adjust made minor adjust core commerci portfolio
reflect current revenu trajectori increas fy revenu estim
non-gaap ep increas
jakafi slightli result guidanc rais mainli pv indic
affirm guidanc unchang sinc result sg estim
guidanc low end rang impli qoq increas
appli similar methodolog estim although
middl rang go forward low quarter re-affirmed high guidanc
impli higher rate spend go forward pipelin progress start
incyt corpor million priorcurrentchangepriorcurrentchangejakafi ruxolitinib sale ruxolitinib royalti revenu loss incom cs dilut cs charl martineau pm univers toronto octob
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
